title: Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
abstract: Urokinase-type plasminogen activator (u-PA) plays a key role in malignant tumor behavior. We have previously shown that the expression of high levels of u-PA mRNA in human hepatocellular carcinoma (HCC) biopsies was inversely correlated with the survival of the patients. In order to evaluate the involvement of u-PA in the invasive and infiltrating properties of HCC cells, the SKHep1C3 cell line was stably transfected with an expression vector containing the 5' portion (257 bp) of u-PA cDNA in the antisense orientation. u-PA mRNA expression and its protein level and enzymatic activity were specifically inhibited in the antisense transfectants. A comparable inhibition of the u-PA receptor (u-PAR) mRNA and protein was also evidenced in the antisense transfected cells compared with the control ones. At the functional level, the SKHep1C3-AS cells showed a significant reduction in proliferation, Matrigel invasion, and motility assays compared to parental and vector-alone cells. These results indicate that u-PA is an essential factor in the growth and invasiveness of human hepatocarcinoma cells. Antisense u-PA strategy might be a potential approach to reduce tumor growth as well as the invasive capacity of the malignant cells in HCC.
authors.affiliation: Division of Biology and Genetics, Department of Biomedical Sciences and Biotechnology, IDET Center of Excellence, University of Brescia, Brescia, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Tavian
authors.forename: Alessandro
authors.initials: A
authors.lastname: Salvi
authors.forename: Giuseppina
authors.initials: G
authors.lastname: De Petro
authors.forename: Sergio
authors.initials: S
authors.lastname: Barlati
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002465:Cell Movement / Q000235:genetics; D005455:Fluorescent Antibody Technique; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D015151:Immunoblotting; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009361:Neoplasm Invasiveness; D016133:Polymerase Chain Reaction / Q000379:methods; D016372:RNA, Antisense / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D014162:Transfection; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: C524898:PLAUR protein, human; D016372:RNA, Antisense; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator